全球并购“向东看”！小摩投行主席：从生物医药到前沿科技，资本正重新审视中国创新价值_老虎社区_美港股上老虎

全球并购“向东看”！小摩投行主席：从生物医药到前沿科技，资本正重新审视中国创新价值

智通财经05-21

智通财经APP获悉，摩根大通全球投行业务主席Anu Aiyengar在接受采访时表示，随着经济与地缘政治风险不断加剧，全球企业愈发渴望与中国具有创新活力的公司合作，推动并购交易热潮持续升温。在当下各大企业高管纷纷依托产业规模优势与并购整合手段来应对全球波动的背景下，2026年全球并购交易规模有望再度创下历史新高。Aiyengar指出，欧美企业日益认为，在动荡时期，与中国成熟的行业领先企业联手，比...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2637800983?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-05-21 19:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2637800983","market":"hk","top_or_hot":-1,"title":"全球并购“向东看”！小摩投行主席：从生物医药到前沿科技，资本正重新审视中国创新价值","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，摩根大通全球投行业务主席Anu Aiyengar在接受采访时表示，随着经济与地缘政治风险不断加剧，全球企业愈发渴望与中国具有创新活力的公司合作，推动并购交易热潮持续升温。在当下各大企业高管纷纷依托产业规模优势与并购整合手段来应对全球波动的背景下，2026年全球并购交易规模有望再度创下历史新高。Aiyengar指出，欧美企业日益认为，在动荡时期，与中国成熟的行业领先企业联手，比...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1444653.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>全球并购“向东看”！小摩投行主席：从生物医药到前沿科技，资本正重新审视中国创新价值</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n全球并购“向东看”！小摩投行主席：从生物医药到前沿科技，资本正重新审视中国创新价值\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-21 19:12 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1444653.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，摩根大通全球投行业务主席Anu Aiyengar在接受采访时表示，随着经济与地缘政治风险不断加剧，全球企业愈发渴望与中国具有创新活力的公司合作，推动并购交易热潮持续升温。在当下各大企业高管纷纷依托产业规模优势与并购整合手段来应对全球波动的背景下，2026年全球并购交易规模有望再度创下历史新高。Aiyengar指出，欧美企业日益认为，在动荡时期，与中国成熟的行业领先企业联手，比...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1444653.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999002224.SGD","symbol_name":"Allianz Global High Payout SGD","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1444653.html","article_id":"2637800983","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2637800983","pubTimestamp":1779361957,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"她进一步补充道：“中国在生物医药、前沿科技领域的创新成果层出不穷，外界对中国的认知正迎来全新转变，这一发展趋势十分良性。”随着大批药品专利即将到期，全球制药企业争相引进中国研发的试验性新药授权，以此压缩研发生产成本。政治因素重塑交易版图在特朗普访华期间，中美双方同意设立投资委员会，旨在促进非敏感领域跨境资本流动。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"161726":"生物医药","399441":"生物医药","SG9999002224.SGD":"Allianz Global High Payout SGD","BK4504":"桥水持仓","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","LU1670627923.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) ACC","IE00BHPRN162.USD":"BNY MELLON BLOCKCHAIN INNOVATION \"B\" (USD) ACC","LU2552382058.USD":"WELLINGTON US BRAND POWER \"A\" (USD) ACC","BK4550":"红杉资本持仓","LU0106831901.USD":"贝莱德世界金融基金A2","LU0882574139.USD":"富达环球消费行业基金A ACC","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC","XBI":"SPDR S&P Biotech ETF","JPO":"JPM期权收益策略ETF-YieldMax","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC","JPMO":"JPM期权收益策略ETF-YieldMax","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","LU1629891620.HKD":"ALLIANZ INCOME AND GROWTH \"AMG2\" (H2-HKD) INC","LU2592432038.USD":"WELLINGTON MULTI-ASSET HIGH INCOME \"A\" (USD) ACC","LU2746668461.USD":"MANULIFE DYNAMIC LEADERS \"AA\" (USD) ACC","LU2430703095.HKD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4\" (HKD) INC","LU0345769631.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) INC","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","LU2430703178.SGD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (SGDHDG) INC","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","LU0211326839.USD":"TEMPLETON GLOBAL INCOME \"A\" (USD) INC","LU2213496289.HKD":"ALLIANZ INCOME AND GROWTH \"AT\" (HKD) ACC","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","BK4585":"ETF&股票定投概念","LU2552382215.SGD":"WELLINGTON US BRAND POWER \"A\" (SGDHDG) ACC","LU0496365809.HKD":"TEMPLETON GLOBAL INCOME \"A\" (HKD) INC (Q)","BK4534":"瑞士信贷持仓","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","IE00BWXC8680.SGD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5\" (SGD) ACC","JPX":"Defiance Daily Target 2X Long JPM ETF","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU0211326755.USD":"TEMPLETON GLOBAL INCOME \"A\" (USD) ACC","LU1496350502.SGD":"FRANKLIN DIVERSIFIED DYNAMIC \"A\" (SGDHDG) ACC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","LU2746668974.SGD":"MANULIFE DYNAMIC LEADERS \"AA\" (SGDHDG) ACC","LU2023250843.SGD":"Allianz Thematica Cl AT Acc H2-SGD","LU0265550359.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A2\" (USD) ACC","BK4566":"资本集团","LU1917777945.USD":"安联专题基金Cl AT Acc","LU2505996509.AUD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (AUDHDG) INC","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)"},"translate_title":"Global mergers and acquisitions \"look east\"! Chairman of Xiaomo Investment Bank: From biomedicine to cutting-edge technology, capital is re-examining China's innovation value","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"161726":1.5,"399441":1.5,"JPX":0.6,"XBI":1.5,"JPO":0.6,"JPMO":0.6},"content_text":"智通财经APP获悉，摩根大通全球投行业务主席Anu Aiyengar在接受采访时表示，随着经济与地缘政治风险不断加剧，全球企业愈发渴望与中国具有创新活力的公司合作，推动并购交易热潮持续升温。在当下各大企业高管纷纷依托产业规模优势与并购整合手段来应对全球波动的背景下，2026年全球并购交易规模有望再度创下历史新高。Aiyengar指出，欧美企业日益认为，在动荡时期，与中国成熟的行业领先企业联手，比单打独斗更具可行性。她直言：“无论是合作、联盟还是收购，都在考量范围之内。”她进一步补充道：“中国在生物医药、前沿科技领域的创新成果层出不穷，外界对中国的认知正迎来全新转变，这一发展趋势十分良性。”这一转变在医药行业体现得尤为明显。随着大批药品专利即将到期，全球制药企业争相引进中国研发的试验性新药授权，以此压缩研发生产成本。业内分析师预计，今年此类药品授权合作交易规模将再度刷新纪录。LSEG数据显示，2026年亚太地区(除日本外)并购活动显著回升，交易量同比增长57%，创下自2022年以来的最强开局。政治因素重塑交易版图在特朗普访华期间，中美双方同意设立投资委员会，旨在促进非敏感领域跨境资本流动。与此同时，大额并购交易数量持续攀升。LSEG数据显示，去年交易金额达到或超过100亿美元的交易达68宗，创历史新高，是2024年数据的两倍。Aiyengar表示：“如今市场愈发青睐头部规模企业，同行业内规模更大的企业往往能获得更高估值溢价。”中国企业海外投资布局同样势头迅猛。荣鼎咨询数据显示，2026年一季度中国企业境外并购投资额达96亿美元，创下2021年初以来新高，同时实现连续五个季度环比增长。其中矿业与能源领域投资最为活跃，今年1月紫金矿业(02899)斥资40亿美元收购加拿大Allied Gold便是典型案例。特朗普第二任期执政期间，政策频繁变动，加之中美、俄美关系起伏不定，进一步加剧全球市场不确定性，极大增加了企业长远战略布局的难度。对此Aiyengar表示，摩根大通建议合作客户“不要根据短期消息做出长期决策”，而是应构建灵活应变的能力，并“增加更多可调控的杠杆”。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}